Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.

ASCO 2025 abstract 5502 of the CALLA NeXT Personal analysis: baseline ctDNA detection 99%; 6-month detection 23% with durvalumab+CRT vs 36% with CRT; baseline median ctDNA 5,268.2 ppm; PFS HRs for low vs high baseline ctDNA 0.57 (0.26–1.26) with D+CRT and 0.62 (0.31–1.23) with CRT.

ASCO Annual Meeting 2025, Abstract 5502 2025